Alnylam Pharmaceuticals, Inc. (ALNY) DCF Valuation
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Alnylam Pharmaceuticals, Inc. (ALNY) Bundle
Whether you’re an investor or an analyst, this (ALNY) DCF Calculator is your go-to resource for accurate valuation. Loaded with real data from Alnylam Pharmaceuticals, Inc., you can adjust forecasts and instantly observe the effects.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 219.8 | 492.9 | 844.3 | 1,037.4 | 1,828.3 | 3,064.3 | 5,135.9 | 8,607.9 | 14,427.2 | 24,180.6 |
| Revenue Growth, % | 0 | 124.28 | 71.31 | 22.88 | 76.23 | 67.6 | 67.6 | 67.6 | 67.6 | 67.6 |
| EBITDA | -868.1 | -736.3 | -661.6 | -926.6 | -258.2 | -2,339.9 | -3,921.7 | -6,572.9 | -11,016.5 | -18,464.1 |
| EBITDA, % | -395.03 | -149.4 | -78.36 | -89.31 | -14.12 | -76.36 | -76.36 | -76.36 | -76.36 | -76.36 |
| Depreciation | 17.2 | 34.8 | 47.6 | 44.5 | 54.1 | 170.1 | 285.0 | 477.7 | 800.6 | 1,341.9 |
| Depreciation, % | 7.82 | 7.06 | 5.63 | 4.29 | 2.96 | 5.55 | 5.55 | 5.55 | 5.55 | 5.55 |
| EBIT | -885.3 | -771.1 | -709.1 | -971.0 | -312.3 | -2,418.8 | -4,054.0 | -6,794.6 | -11,388.1 | -19,086.8 |
| EBIT, % | -402.85 | -156.46 | -83.99 | -93.6 | -17.08 | -78.93 | -78.93 | -78.93 | -78.93 | -78.93 |
| Total Cash | 1,536.2 | 1,874.4 | 2,435.6 | 2,192.4 | 2,439.4 | 3,064.3 | 5,135.9 | 8,607.9 | 14,427.2 | 24,180.6 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 43.0 | 102.4 | 198.6 | 238.0 | 327.8 | 641.9 | 1,075.8 | 1,803.2 | 3,022.2 | 5,065.3 |
| Account Receivables, % | 19.57 | 20.78 | 23.52 | 22.94 | 17.93 | 20.95 | 20.95 | 20.95 | 20.95 | 20.95 |
| Inventories | 56.3 | 92.3 | 122.7 | 129.0 | 89.1 | 467.1 | 782.8 | 1,312.0 | 2,199.0 | 3,685.6 |
| Inventories, % | 25.64 | 18.73 | 14.53 | 12.43 | 4.88 | 15.24 | 15.24 | 15.24 | 15.24 | 15.24 |
| Accounts Payable | 49.9 | 52.0 | 73.4 | 98.1 | 55.5 | 333.6 | 559.1 | 937.1 | 1,570.6 | 2,632.5 |
| Accounts Payable, % | 22.7 | 10.54 | 8.7 | 9.46 | 3.04 | 10.89 | 10.89 | 10.89 | 10.89 | 10.89 |
| Capital Expenditure | -140.2 | -70.4 | -76.4 | -72.1 | -62.2 | -597.2 | -1,001.0 | -1,677.7 | -2,811.9 | -4,712.8 |
| Capital Expenditure, % | -63.78 | -14.28 | -9.05 | -6.95 | -3.4 | -19.49 | -19.49 | -19.49 | -19.49 | -19.49 |
| Tax Rate, % | -1.55 | -1.55 | -1.55 | -1.55 | -1.55 | -1.55 | -1.55 | -1.55 | -1.55 | -1.55 |
| EBITAT | -886.1 | -773.5 | -709.7 | -974.6 | -317.1 | -2,418.8 | -4,054.0 | -6,794.6 | -11,388.1 | -19,086.8 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -1,058.6 | -902.4 | -843.6 | -1,023.2 | -417.9 | -3,259.9 | -5,294.1 | -8,873.1 | -14,871.7 | -24,925.6 |
| WACC, % | 6.13 | 6.13 | 6.13 | 6.13 | 6.13 | 6.13 | 6.13 | 6.13 | 6.13 | 6.13 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -45,434.1 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -25,424 | |||||||||
| Terminal Value | -616,075 | |||||||||
| Present Terminal Value | -457,624 | |||||||||
| Enterprise Value | -503,058 | |||||||||
| Net Debt | 1,870 | |||||||||
| Equity Value | -504,928 | |||||||||
| Diluted Shares Outstanding, MM | 125 | |||||||||
| Equity Value Per Share | -4,042.46 |
What You Will Get
- Real Alnylam Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures.
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Alnylam’s fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections.
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility.
Key Features
- Comprehensive Financial Data: Gain access to precise historical data and future forecasts for Alnylam Pharmaceuticals, Inc. (ALNY).
- Adjustable Forecast Parameters: Modify highlighted cells for key metrics such as WACC, growth rates, and profit margins.
- Real-Time Calculations: Automatic recalculations for DCF, Net Present Value (NPV), and cash flow assessments.
- Interactive Dashboard: User-friendly charts and summaries to help visualize valuation outcomes.
- Designed for All Skill Levels: An intuitive layout tailored for investors, financial officers, and consultants alike.
How It Works
- Download: Get the pre-configured Excel file containing Alnylam Pharmaceuticals' financial data.
- Customize: Modify projections such as revenue growth, EBITDA %, and WACC as needed.
- Update Automatically: Watch the intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Develop various projections and analyze results immediately.
- Make Decisions: Leverage the valuation findings to inform your investment strategy for Alnylam Pharmaceuticals, Inc. (ALNY).
Why Choose This Calculator for Alnylam Pharmaceuticals, Inc. (ALNY)?
- Accurate Data: Up-to-date Alnylam financials provide trustworthy valuation outcomes.
- Customizable: Modify essential parameters such as growth rates, WACC, and tax rates to align with your forecasts.
- Time-Saving: Ready-to-use calculations save you from starting from the ground up.
- Professional-Grade Tool: Crafted for investors, analysts, and consultants focused on biotechnology.
- User-Friendly: Clear layout and guided instructions ensure ease of use for everyone.
Who Should Use This Product?
- Healthcare Investors: Develop comprehensive and accurate valuation models for investment decisions in biotech.
- Corporate Strategy Teams: Evaluate valuation scenarios to inform strategic initiatives within the organization.
- Consultants and Advisors: Deliver precise valuation insights for Alnylam Pharmaceuticals, Inc. (ALNY) to clients.
- Students and Educators: Utilize real-world data to enhance learning and practice in financial modeling.
- Biotech Enthusiasts: Gain insights into how companies like Alnylam Pharmaceuticals, Inc. (ALNY) are valued in the healthcare market.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Alnylam Pharmaceuticals historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Alnylam Pharmaceuticals, Inc. (ALNY).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.